ADR
Director Trades
| Date | Director | Value |
|---|
Company News
Market wrap: Australian market follows Wall Street down
Once again, an Australian encore followed a Wall Street sell-off as investors grew increasingly nervous about the prospect for rate falls, with bond yields rising and shares in interest rate sensitive areas falling. Weakness in commodity prices didn’t help the Australian market, with falling prices for iron ore and gold helping to broaden the decline […]
Adherium partners with AstraZeneca for Hailie Smartinhaler clinical trial
Digital health solutions specialist Adherium (ASX: ADR) is celebrating news that global biopharmaceutical giant AstraZeneca has selected its Hailie Smartinhaler platform for a clinical trial. Under the contract, valued at $1.1 million, AstraZeneca will use the devices to record and transfer medication usage data over a period of three years. Adherium will provide Hailie Smartinhalers, […]
Adherium’s Hailie Smartinhaler receives FDA approval for use with leading AstraZeneca devices
Medical device developer Adherium (ASX: ADR) has been given clearance by the US Food and Drug Administration (FDA) for its Hailie Smartinhaler to be used with AstraZeneca’s Airsupra and Breztri inhalation devices. Airsupra is the first FDA-approved rescue medication for asthma patients and Breztri is a triple combination for patients with chronic obstructive pulmonary disorder […]
Adherium joins forces with US health group to offer remote medical management for high-risk respiratory patients
New Zealand-based Adherium (ASX: ADR) is set to form a collaborative alliance with US-based HGE Health to remotely evaluate, treat and manage patients with severe asthma and chronic obstructive pulmonary disease. The respiratory device manufacturer will integrate its own sensor and software technology into HGE Health’s established telemedicine platform to provide better overall health care […]
Adherium receives FDA grant to market Smartinhaler in the US
Medical device manufacturer Adherium (ASX: ADR) has secured a crucial go-ahead decision from the Food and Drug Administration (FDA) in the US. Earlier today, Adherium was granted 510(k) clearance for over-the-counter (OTC) sales of its Smartinhaler sensor for AstraZeneca’s Symbicort aerosol asthma inhaler. The devices and accompanying technology address sub-optimal medication use and strive to […]
Adherium directors rally around internal mission to progress Smartinhaler technology
Medical device manufacturer Adherium (ASX: ADR) has highlighted its own optimism and confidence regarding its progress in developing a novel way for delivering drug treatments to patients. Adherium is developing a novel method of introducing drug treatments to patients and intends to make its Smartinhaler range available on a wider scale, backed up by strong […]
Adherium looks to jumpstart medication uptake rates via Smartinhaler
Medical device manufacturer Adherium (ASX: ADR) is working on a potentially seismic shift in how medicine is consumed by patients. In a presentation to the Joint Congress of the American Academy of Allergy Asthma and Immunology and the World Allergy Organization in Orlando last week, Adherium presented fresh study results regarding its Smartinhaler technology. Adherium’s […]